Spinal Muscular Atrophy Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026

1. Spinal Muscular Atrophy Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026 Spinal Muscular Atrophy Market, by Disease Type (Type I, Type II, Type III, Type IV), by Treatment (Gene Therapy and Drugs), by Age (Infant and Adult), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026 Spinal muscular atrophy (SMA) is a rare, genetically inherited neuromuscular condition. The disease causes loss of movement and progressive muscle weakness due to muscle wasting (atrophy). The disease is divided into four subtypes (1 to 4) on the basis of the age of onset. SMA type 1 (SMA1) is the most severe form and most common genetic cause of death among infants. Various drugs are available in the market to treat the symptoms of the diseases, however, only one drug is approved for the treatment of SMA so far. Muscle relaxants such as tizanidine, baclofen, and the benzodiazepines can reduce spasticity. Excessive saliva can be treated with glycopyolate, amitriptyline, and atropine or by botulinum injections into the salivary glands. Antidepressants can be helpful in treating depression. Botulinum toxin can also be used to treat drooling or jaw spasms. Download PDF Brochure of Market Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1920 Market Dynamics Major factors driving growth of the spinal muscular atrophy market includes increasing number of clinical trials and rising government support for R&D. Biotechnology and biopharmaceutical companies are working towards development of efective therapies to treat spinal muscular atrophy. For instance, in 2016, the U.S. FDA approved Spinraza (nusinersen) drug from Biogen for the treatment of SMA. Spinraza targets the underlying defect in SMA, so it can help prevent, delay, or even reverse the symptoms. However, its common side efects include higher risk of constipation and respiratory tract infection along with minimal risk of kidney problems and bleeding. Moreover, the cost of

2. research for development of new therapy is also high. With the advancements of drug in the pipeline, its expense and time for development also increases. According to Cure SMA, it can take over 15 years and US$ 100 million for a single drug candidate to reach FDA approval. These factors make research challenging particularly for a disease such as SMA. These factors are expected to hinder growth of the market. Browse more about the Deep Brain Stimulation Devices Market Study: https://www.coherentmarketinsights.com/insight/request-customization/1920 Market Players Biogen, Cytokinetics, Inc., F. Hofmannn-a Roche, Novartis AG, Pfzer Inc., and Ionis Pharmaceuticals, Inc. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com